Skip to main content
Larkosis Pharma Logo
Cefpodoxime + Clavulanate Potassium

Category

Antibacterial

Form

Tablets

Strength

100mg / 62.5mg

CAS

87239-81-4 / 61177-45-5

Cefpodoxime + Clavulanate Potassium Tablets – Broad-Spectrum Antibacterial Combination

Cefpodoxime + Clavulanate Potassium Tablets 100mg + 62.5mg are a modern antibacterial combination developed for the management of susceptible bacterial infections. This formulation combines cefpodoxime, an oral third-generation cephalosporin, with clavulanate potassium, a beta-lactamase inhibitor. Clavulanate enhances antibacterial activity by protecting the antibiotic from enzymatic degradation. The combination is positioned as a practical antibacterial solution for institutional buyers, distributors, and healthcare supply partners. CAS references include Cefpodoxime Proxetil 87239-81-4 and Potassium Clavulanate 61177-45-5 for regulatory and procurement documentation.

Cefpodoxime + Clavulanate Potassium Tablets 100mg + 62.5mg represent a commercially strong antibacterial combination. Cefpodoxime proxetil is an oral cephalosporin antibacterial indicated for mild to moderate infections caused by susceptible bacteria. Clavulanate potassium acts as a beta-lactamase inhibitor, preserving antibiotic effectiveness against resistant enzymes. The combination expands antibacterial coverage and improves treatment outcomes. This formulation is widely used for respiratory, ENT, skin, and other bacterial infections depending on physician judgment and local registration.

Request Quote

Overview

  • Combination antibacterial tablet formulation.
  • Contains Cefpodoxime 100mg and Clavulanate Potassium 62.5mg.
  • Designed for mild to moderate infections with beta-lactamase resistance considerations.
  • Oral dosage form suitable for outpatient treatment.
  • Widely used in global antibacterial therapy portfolios.

Introduction

  • Cefpodoxime + Clavulanate Potassium Tablets 100mg + 62.5mg represent a commercially strong antibacterial combination.
  • Cefpodoxime proxetil is an oral cephalosporin antibacterial indicated for mild to moderate infections caused by susceptible bacteria.
  • Clavulanate potassium acts as a beta-lactamase inhibitor, preserving antibiotic effectiveness against resistant enzymes.
  • The combination expands antibacterial coverage and improves treatment outcomes.
  • This formulation is widely used for respiratory, ENT, skin, and other bacterial infections depending on physician judgment and local registration.

Important Information

  • Used for bacterial infections, not viral illnesses such as cold or flu.
  • Commonly used in respiratory, ENT, skin, and soft tissue infections.
  • FDA labeling includes indications such as otitis media, pharyngitis, bronchitis, pneumonia, sinusitis, and skin infections.
  • Clavulanate enhances Cefpodoxime’s resistance profile against beta-lactamase producing bacteria.
  • Combination therapy provides improved effectiveness compared to monotherapy in certain cases.

Storage

  • Store in a cool, dry place
  • Protect from moisture, heat, and direct sunlight
  • Keep tablets in original strip or carton until use
  • Keep out of reach of children
  • Follow approved label storage conditions for the destination market

Shelf Life

  • Shelf life: As per approved stability data and printed expiry on the commercial pack
  • Based on validated stability studies under pharmaceutical guidelines
  • Batch number, manufacturing date, and expiry date must be clearly labeled

Dosage

General

  • Dosage depends on infection severity, patient age, and physician guidance
  • Typically used in short-course oral antibacterial therapy
  • May vary based on renal function and clinical condition

Administration

  • Taken orally as prescribed by a healthcare professional
  • Follow local prescribing information
  • Use according to approved medical guidelines

Important

  • Complete the prescribed antibacterial course
  • Do not use for viral infections
  • Avoid self-medication

Manufacturing

  • Manufactured under stringent pharmaceutical quality systems
  • Qualified API sourcing for cefpodoxime proxetil and potassium clavulanate
  • Validated blending and compression processes
  • Tablet uniformity and assay control
  • Dissolution and disintegration compliance
  • Microbial and stability monitoring
  • Strip-pack integrity and transport suitability
  • Batch traceability and documentation readiness

Precautions

  • Use only for bacterial infections when clinically appropriate
  • Use with caution in patients with cephalosporin or penicillin hypersensitivity
  • Dose adjustment may be required in renal impairment
  • Monitor for Clostridioides difficile-associated diarrhea
  • Complete full course unless advised otherwise by a doctor

Side Effects

  • Diarrhea
  • Nausea
  • Abdominal pain
  • Headache
  • Rash or hypersensitivity reactions
  • Vaginal fungal infection in some cases
  • Rare allergic reactions

Expert View

  • Cefpodoxime + Clavulanate Potassium Tablets provide a balance between oral convenience and antibacterial depth.
  • The addition of clavulanate enhances the resistance profile of cefpodoxime.
  • This formulation is commercially valuable for anti-infective portfolios.
  • It supports treatment where beta-lactamase activity reduces the effectiveness of standard antibiotics.
  • Widely accepted in both branded and generic pharmaceutical markets.

Indications

  • Respiratory tract infections
  • Acute otitis media
  • Pharyngitis and tonsillitis
  • Community-acquired pneumonia
  • Acute bronchitis
  • Sinusitis
  • Skin and soft tissue infections
  • Other susceptible bacterial infections

Maintenance

  • Use as prescribed by a healthcare professional
  • Maintain proper dosing schedule
  • Complete full course of therapy
  • Monitor for side effects or allergic reactions
  • Store properly to maintain product stability

Why Choose

  • Broad-spectrum antibacterial coverage
  • Effective against beta-lactamase producing bacteria
  • Convenient oral dosage form
  • Suitable for mild to moderate infections
  • Strong regulatory and manufacturing support

Frequently Asked Questions

Common product and supply questions.

Can cefpodoxime treat bacterial infections?+

Yes. Cefpodoxime is an oral cephalosporin antibacterial used for mild to moderate infections caused by susceptible bacteria, including respiratory, ENT, and skin infections.

Is cefpodoxime and potassium clavulanate tablets an antibiotic?+

It is an antibacterial combination product. Cefpodoxime is the antibiotic component, while potassium clavulanate helps protect against resistant bacterial enzymes.

What is the antibacterial spectrum of cefpodoxime?+

Cefpodoxime has activity against a range of susceptible organisms associated with respiratory, ENT, and skin infections as listed in approved labeling.

Which antibiotic is stronger, amoxicillin or cefpodoxime?+

Neither is universally stronger. They belong to different classes and are selected based on infection type, bacterial susceptibility, and clinical judgment.

Which bacteria is killed by cefpodoxime?+

Cefpodoxime is used against susceptible bacteria involved in respiratory, sinus, skin, and other infections depending on indication and organism sensitivity.